Amylyx Pharmaceuticals (AMLX) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Organon (OGN) has outperformed Amylyx Pharmaceuticals (AMLX) over the past year, gaining 92.9% versus a gain of 77.4%. Organon is the larger company by market cap ($3.65 billion vs $3.35 billion), about 1.1 times the size. Organon pays a dividend yielding 0.58%, while Amylyx Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | OGN |
|---|---|---|
| Share price | $26.02 | $13.89 |
| Market cap | $3.35B | $3.65B |
| 1-day change | -0.69% | -0.14% |
| YTD return | +115.40% | +93.72% |
| 1-year return | +77.37% | +92.92% |
| 5-year return | — | -55.38% |
| P/E ratio (TTM) | — | 17.81 |
| Forward P/E | — | 3.81 |
| EPS (TTM) | $-1.43 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | $0 | $6.22B |
| Revenue growth (YoY) | -100.00% | -2.92% |
| Net income (latest FY) | $-144.74M | $187.00M |
| Gross margin | — | 53.30% |
| Net margin | — | 3.01% |
| 52-week high | $41.14 | $13.94 |
| 52-week low | $10.83 | $5.69 |
| Distance from 52-week high | -36.75% | -0.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +65.26% | -25.63% |
| Average volume | 1.53M | 2.74M |
| Shares outstanding | 128.56M | 262.62M |
| Employees | 136 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGN has outperformed AMLX by 15.5 percentage points over the past year.
- Organon grew revenue faster in its latest fiscal year (-2.92% vs -100.00%).
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
AMLX vs OGN FAQ
Which is bigger, Amylyx Pharmaceuticals or Organon?
Organon (OGN) is larger, with a market capitalization of $3.65B compared with $3.35B for Amylyx Pharmaceuticals (AMLX).
Which stock has performed better over the past year, AMLX or OGN?
OGN returned +92.92% over the past 12 months, compared with +77.37% for AMLX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amylyx Pharmaceuticals or Organon?
Organon pays a dividend yielding 0.58%, while Amylyx Pharmaceuticals does not currently pay a regular dividend.
Are Amylyx Pharmaceuticals and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.